535,954 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Purchased by Fisher Asset Management LLC

Fisher Asset Management LLC acquired a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 535,954 shares of the biopharmaceutical company's stock, valued at approximately $44,747,000. Fisher Asset Management LLC owned approximately 0.55% of Cytokinetics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of CYTK. Vanguard Group Inc. lifted its stake in shares of Cytokinetics by 4.6% during the third quarter. Vanguard Group Inc. now owns 10,743,324 shares of the biopharmaceutical company's stock worth $316,498,000 after buying an additional 472,595 shares during the period. Assenagon Asset Management S.A. purchased a new stake in Cytokinetics during the 4th quarter valued at about $46,308,000. Rhumbline Advisers increased its holdings in shares of Cytokinetics by 1.1% in the third quarter. Rhumbline Advisers now owns 274,869 shares of the biopharmaceutical company's stock valued at $8,098,000 after purchasing an additional 3,005 shares during the period. Rafferty Asset Management LLC raised its stake in shares of Cytokinetics by 10.0% in the third quarter. Rafferty Asset Management LLC now owns 246,922 shares of the biopharmaceutical company's stock worth $7,274,000 after purchasing an additional 22,498 shares during the last quarter. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Cytokinetics by 84.1% during the third quarter. Affinity Asset Advisors LLC now owns 230,366 shares of the biopharmaceutical company's stock worth $6,787,000 after purchasing an additional 105,218 shares during the period.

Insider Activity at Cytokinetics

In other news, EVP Fady Ibraham Malik sold 32,605 shares of the company's stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $79.30, for a total transaction of $2,585,576.50. Following the completion of the sale, the executive vice president now owns 142,973 shares of the company's stock, valued at $11,337,758.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Cytokinetics news, EVP Fady Ibraham Malik sold 32,605 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $79.30, for a total value of $2,585,576.50. Following the completion of the sale, the executive vice president now owns 142,973 shares in the company, valued at approximately $11,337,758.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John T. Henderson sold 10,562 shares of the business's stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $64.54, for a total value of $681,671.48. Following the transaction, the director now owns 32,070 shares in the company, valued at $2,069,797.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 113,376 shares of company stock valued at $8,275,252. 3.40% of the stock is owned by insiders.

Cytokinetics Stock Performance

Shares of CYTK stock traded up $0.93 on Friday, reaching $65.27. 900,208 shares of the company were exchanged, compared to its average volume of 1,138,180. Cytokinetics, Incorporated has a 1 year low of $25.98 and a 1 year high of $110.25. The business has a 50-day moving average price of $68.57 and a 200 day moving average price of $60.82. The company has a market cap of $6.83 billion, a price-to-earnings ratio of -11.98 and a beta of 0.72.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.35). The business had revenue of $1.70 million during the quarter, compared to the consensus estimate of $7.62 million. The company's quarterly revenue was down 10.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.45) EPS. As a group, equities analysts anticipate that Cytokinetics, Incorporated will post -4.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CYTK. HC Wainwright reissued a "buy" rating and set a $94.00 price target on shares of Cytokinetics in a research report on Wednesday, February 28th. Oppenheimer reaffirmed an "outperform" rating and set a $107.00 price target on shares of Cytokinetics in a research report on Monday, March 4th. StockNews.com cut Cytokinetics from a "hold" rating to a "sell" rating in a report on Friday, January 5th. Needham & Company LLC restated a "buy" rating and issued a $108.00 target price on shares of Cytokinetics in a research note on Tuesday, April 9th. Finally, UBS Group cut Cytokinetics from a "buy" rating to a "neutral" rating and lifted their price target for the company from $61.00 to $92.00 in a research report on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $79.33.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.